Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$7.50 USD
+0.21 (2.88%)
Updated May 3, 2024 04:00 PM ET
After-Market: $7.55 +0.05 (0.67%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Mesoblast Limited (MESO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$4.00 | $4.00 | $4.00 | -45.13% |
Price Target
Only one analyst offered a short-term price target of $4.00 for Mesoblast Limited. This represents a decline of 45.13% from the last closing price of $7.29.
Analyst Price Targets (1 )
Broker Rating
Mesoblast Limited currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, two are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/16/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
3/12/2024 | Piper Sandler | Edward A Tenthoff | Hold | Hold |
8/7/2023 | Maxim Group | Michael Okunewitch | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 4 |
Average Target Price | $4.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 252 |
Current Quarter EPS Est: | NA |